Latest Breaking News On - Rheumatology convergence - Page 3 : comparemela.com

Rituximab Plus Avacopan Increases Remission Rates in ANCA-Associated Vasculitis

Sustained remission was observed in more patients receiving rituximab and concomitant avacopan compared with those treated with concomitant prednisone.

Fierce Biotech Bureau of Investigations seeks ACR poster burglar

Ryan DeMasi, MD: Long-Term Safety, Efficacy of Risankizumab in Patients with Psoriatic Arthritis

The 148-week study evaluated multiple domains of patients with psoriatic arthritis receiving risankizumab treatment, providing insights into patients' improvement over time.

Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

15.11.2023 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for . Seite 1

Telitacicept Efficacious, Safe in Treating Rheumatoid Arthritis Patients with Inadequate MTX Response

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in ACR20, ACR50, and DAS28-ESR responses.